Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Waldenstrom Macroglobulinemia × obinutuzumab × Clear all

Phase

Status

Unknown 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 30 Lymphoma, Follicular 16 Lymphoma, Non-Hodgkin 14 Lymphoma 10 Lymphoma, Mantle-Cell 7 Lymphoma, Large B-Cell, Diffuse 7 Lymphoma, B-Cell, Marginal Zone 6 Lymphoma, B-Cell 5 Recurrence 4 Neoplasms 2 Leukemia, Hairy Cell 2 Waldenstrom Macroglobulinemia 1 Uveal Melanoma 1 Tumor Lysis Syndrome 1 Solid Cancers 1 Oncology Patients Receiving Chemotherapy 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Melanoma 1 Leukemia, Prolymphocytic, B-Cell 1 Leukemia, Prolymphocytic 1 Leukemia, Lymphoid 1 Leukemia, B-Cell 1 Leukemia 1 Disease 1 Colorectal Neoplasms 1 Chromosome 17 deletion 1 Carcinoma, Non-Small-Cell Lung 1 Bronchiolitis Obliterans Syndrome 1 Anemia 1

Interventions

Rituximab 50 Cyclophosphamide 35 fludarabine phosphate 31 Peripheral Blood Stem Cell Transplantation 30 Whole-Body Irradiation 22 Mycophenolic Acid 21 Bortezomib 20 Dexamethasone 19 Cyclosporine 17 Etoposide 14 Filgrastim 13 Busulfan 12 ibrutinib 11 Tacrolimus 11 Radiotherapy 11 Melphalan 10 Antilymphocyte Serum 10 Methotrexate 9 Calcium Dobesilate 9 Lenalidomide 7 Everolimus 7 Cyclosporins 7 Sirolimus 6 Carboplatin 6 zanubrutinib 5 ibritumomab tiuxetan 5 Prednisone 5 In Situ Hybridization, Fluorescence 5 Flow Cytometry 5 thymoglobulin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02962401 2023-08-29

RemodelWM3

French Innovative Leukemia Organisation

Phase 2 Completed

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡